蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 2205|回复: 8
收起左侧

[GMP相关] 药品监管联合联盟—GMP检查行动计划蓝图(2016.12)

[复制链接]
药士
发表于 2017-10-20 14:05:17 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
What are the current GMP Inspection Initiatives?

  
The International Coalition of Medicines Regulatory Authorities (ICMRA) has published a very interesting overview about the current global GMP inspection initiatives by the competent authorities. It also shows the various initiatives between the EU and the US Food and Drug Administration (FDA):

EMA/FDA/TGA API Programme

This programme of the European Medicines Agency (EMA), the European Directorate of the Quality of Medicines and Healthcare (EDQM), the European National Supervisory Authorities, the US Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA) and the World Health Organization (WHO) tries to foster the cooperation and mutual confidence between the participants through better communication and exchange of information on inspection planning. It covers joint inspections of API manufacturers located outside the participating regions but also the reliance on API inspections by other authorities.

(该项目为EMA/EDQM/EU各成员国监管机构/FDA/TGA/WHO沟通各自的API检查计划,包括实施对参与国以外的API场地进行联合检查,同时该其他国家监管机构可以依靠该API场地检查结果,或者代表其他国家监管机构进行扩展API场地检查。这个以前海正就被联合检查了)

EMA/FDA Mutual reliance Confidence building

The overall objective of this initiative is to allow some inspections on each others' territories to be deferred or waived completely based on a number of considerations.

(该项目为EMA/FDA可以互相依靠各自对其国内生产场地的检查结果。这个已经达成)

EMA/FDA Finished Products programme

This programme is closely related to the one above. Here, EMA and FDA are evaluating whether greater international collaboration can help to better distribute inspection capacity, allowing more sites to be monitored and reducing unnecessary duplication, limited to inspections of manufacturers of human medicinal (finished drug) products which come under the authority of FDA's Center for Drug Evaluation and Research and the centralised marketing authorisation process in the EU.

(该项目为针对于人药制剂(CDER和EMA集中审评管理下的制剂),采用EMA/FDA联合检查的形式,对两国以外的生产场地进行检查)

PIC/S Pharmaceutical Inspection Co-operation Scheme

Inspectorates from various EU Member States and the FDA are member of PIC/S which tries to foster the international co-operation in the field of GMP by developing and promoting harmonised GMP standards and guidance documents, training GMP inspectors, assessing (and reassessing) GMP inspectorates and facilitating co-operation and networking and planning of inspection.

The International Coalition of Medicines Regulatory Authorities (ICMRA) is a voluntary, executive-level, strategic coordinating, advocacy and leadership entity of regulatory authorities that work together to

  • address current and emerging human medicine regulatory and safety challenges globally, strategically and in an ongoing, transparent, authoritative and institutional manner
  • provide direction for areas and activities common to many regulatory authorities' missions
  • identify areas for potential synergies
  • wherever possible, leverage existing initiatives/enablers and resources

ICMRA wants to provide a global architecture to support enhanced communication, information sharing, crisis response and address regulatory science issues.

The overview is available as ICMRA - Mapping of GMP Inspection Initiatives



mapping of GMP inspection initiatives.pdf

102.18 KB, 下载次数: 22

回复

使用道具 举报

药士
 楼主| 发表于 2017-10-20 14:13:06 | 显示全部楼层
mapping中除了上面的联合行动外,还有其他行动内容。
其实中国和印度均被排除在外,如果这些行动计划逐步实施,后期的中国国内的国外监管严峻,除了检查频次增多,同时被这些所谓的严格监管机构(SRA,stringent reglatory agencies)检查的结果,可能会得到世界其他国家的在程序层面的认可,从而造成GMP不合规的代价极大。
回复

使用道具 举报

药士
 楼主| 发表于 2017-10-20 14:13:06 | 显示全部楼层
mapping中除了上面的联合行动外,还有其他行动内容。
其实中国和印度均被排除在外,如果这些行动计划逐步实施,后期的中国国内的国外监管严峻,除了检查频次增多,同时被这些所谓的严格监管机构(SRA,stringent reglatory agencies)检查的结果,可能会得到世界其他国家的在程序层面的认可,从而造成GMP不合规的代价极大。
回复

使用道具 举报

药士
 楼主| 发表于 2017-10-20 14:13:14 | 显示全部楼层
mapping中除了上面的联合行动外,还有其他行动内容。
其实中国和印度均被排除在外,如果这些行动计划逐步实施,后期的中国国内的国外监管严峻,除了检查频次增多,同时被这些所谓的严格监管机构(SRA,stringent reglatory agencies)检查的结果,可能会得到世界其他国家的在程序层面的认可,从而造成GMP不合规的代价极大。
回复

使用道具 举报

药徒
发表于 2017-10-20 14:25:20 | 显示全部楼层
beiwei5du 发表于 2017-10-20 14:13
mapping中除了上面的联合行动外,还有其他行动内容。
其实中国和印度均被排除在外,如果这些行动计划逐步 ...

重要的话说三遍?
回复

使用道具 举报

药士
发表于 2017-10-20 16:05:59 | 显示全部楼层
回复

使用道具 举报

药徒
发表于 2017-10-28 20:13:39 | 显示全部楼层
形势严峻啊
回复

使用道具 举报

药徒
发表于 2017-12-27 13:56:49 | 显示全部楼层
好资料,收藏了


论坛发金币帖子任意门
https://www.ouryao.com/forum.php? ... &fromuid=295574
论坛秘笈:每周赚1000积分不再是神话
https://www.ouryao.com/forum.php? ... &fromuid=295574
新手30分钟赚取200积分标准操作规程
https://www.ouryao.com/forum.php? ... &fromuid=295574
回复

使用道具 举报

药王
发表于 2023-1-17 21:55:37 | 显示全部楼层
非常感谢分享
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-7-25 16:10

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表